| Income Statement | 2025-09-30 | 2025-06-30 | 2025-03-31 | 2024-09-30 |
|---|---|---|---|---|
| Collaboration and license revenue | 90 | 15 | 14 | 3 |
| Research and development | 49,438 | 47,951 | 40,699 | 38,484 |
| General and administrative | 11,837 | 11,520 | 12,936 | 12,651 |
| Total operating expenses | 61,275 | 59,471 | 53,635 | 51,135 |
| Loss from operations | -61,185 | -59,456 | -53,621 | -51,132 |
| Interest income | 4,330 | 4,859 | 5,582 | 7,290 |
| Other income (expense), net | -21 | -61 | 67 | -1 |
| Total other income, net | 4,309 | 4,798 | 5,649 | 7,289 |
| Net loss | -56,876 | -54,658 | -47,972 | -43,843 |
| Earnings per share, basic | -1.01 | -0.98 | -0.86 | -0.79 |
| Earnings per share, diluted | -1.01 | -0.98 | -0.86 | -0.79 |
| Weighted average number of shares outstanding, basic | 56,126,330 | 55,927,091 | 55,744,047 | 55,554,476 |
| Weighted average number of shares outstanding, diluted | 56,126,330 | 55,927,091 | 55,744,047 | 55,554,476 |
4D Molecular Therapeutics, Inc. (FDMT)
4D Molecular Therapeutics, Inc. (FDMT)